DV
Dividend Vision

MNKD — MannKind Corporation

MannKind Corporation (MNKD)

Total return is -94.5% over the past 22 years, 1052.0 points behind SPY at 957.5%. Its deepest 1-year drawdown was 63.3%.

MNKD is a single-stock equity fund tracking MannKind Corporation, a biopharmaceutical company focused on drug delivery systems and diabetes care treatments. The fund does not currently pay distributions, has no stated expense ratio, and carries the risks associated with concentrated single-stock exposure rather than diversified portfolio construction. This structure appeals primarily to investors seeking direct equity participation in MannKind rather than those seeking dividend income or broad market diversification.

MNKD key facts

Asset type
Stock
Asset class
Equity
Inception date
07/28/2004
Last close
$3.85
Market cap
$1,229,655,296
Average volume
2855300.0
Payment date
03/03/2017
Beta
1.099
Payout ratio
0.0
Forward P/E
112.3596
EPS
$-0.15